

MUGARD (carbomer; glycerin; polysorbate)

Effective Date: 1/28/14

Date Developed: 1/28/14 by Robert Sterling, MD

Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19, 2/18/20,
2/2/21, 8/3/21, 2/1/22, 1/31/23, 2/13/24, 2/18/25

Mugard is an oral mucosal barrier gel that forms a protective coating over the oral mucosa.

Other brand names for this product include Gelclair, Mucotrol, Orafate and PrThelial

Authorization: For-

Management of oral mucosal pain and protection from further irritation caused by oral mucositis/stomatitis (resulting from chemotherapy or radiation therapy); oral lesions, periodontal and gingival inflammation, tooth extractions, and wounds/lesions due to oral surgery; traumatic ulcers, and abrasions caused by braces/ill-fitting dentures or disease; diffuse aphthous ulcers; sore throat/pharyngitis.

Dosing: Rinse with 5 mL 4 to 6 times daily (for oral mucositis/stomatitis) or 4 to 6 times daily or as needed (for other ulcerative conditions); may use up to 10 mL if needed to fully coat inside of mouth.

May use up to 10mL to fully coat inside of mouth. Do not dilute. After rinsing, expel or swallow. Avoid eating or drinking for at least 1 hour after rinsing. Not recommended for children.

PRECAUTIONS: May decrease absorption of sublingually administered medications.

REFERENCES

1. MuGard [product information]. Waltham, MA: AMAG Pharmaceuticals Inc; December 2014
2. Vokurka S, Skardova J, Hruskova R, et al, "The Effect of Polyvinylpyrrolidone-Sodium Hyaluronate Gel (Gelclair) on Oral Microbial Colonization and Pain Control Compared With Other Rinsing Solutions in Patients With Oral Mucositis After Allogeneic Stem Cells Transplantation," Med Sci Monit, 2011, 17(10):CR572-6.
3. Barber C, Powell R, Ellis A, et al, "Comparing Pain Control and Ability to Eat and Drink With Standard Therapy vs Gelclair: A Preliminary, Double Centre, Randomized Controlled Trial on Patients With Radiotherapy-Induced Oral Mucositis," Support Care Cancer, 2007, 15(4):427-40.

Revision History:

Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
Date Approved by P&T Committee: 1/27/15
Date Reviewed/No Updates: 1/26/16 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/26/16
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/23/18
Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/22/19
Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/18/20
Date Reviewed/No Updates: 2/2/21 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/2/21
Date Reviewed/No Updates: 8/3/21 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 8/3/21
Date Reviewed/No Updates: 2/1/22 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/1/22
Date Reviewed/No Updates: 1/31/23 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/31/23
Date Reviewed/Updated: 2/18/25 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/18/25

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
2/18/20	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
2/2/21	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
8/3/21	Yes	Howard Taekman, MD; Robert Sterling, MD	Updated description and references
2/1/22	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
1/31/23	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
2/13/24	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
2/18/25	Yes	Howard Taekman, MD; Robert Sterling, MD	Updated description, authorization, dosing and precaution sections